Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Algert Global LLC

Algert Global LLC cut its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 84.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,720 shares of the company’s stock after selling 97,959 shares during the period. Algert Global LLC’s holdings in Protagonist Therapeutics were worth $684,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Franklin Resources Inc. lifted its holdings in Protagonist Therapeutics by 127.2% in the third quarter. Franklin Resources Inc. now owns 81,591 shares of the company’s stock valued at $3,782,000 after acquiring an additional 45,674 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in Protagonist Therapeutics by 3,099.4% in the third quarter. Principal Financial Group Inc. now owns 320,832 shares of the company’s stock valued at $14,437,000 after acquiring an additional 310,804 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Protagonist Therapeutics by 36.7% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 216,069 shares of the company’s stock worth $8,340,000 after purchasing an additional 58,002 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in Protagonist Therapeutics during the fourth quarter worth $2,016,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in Protagonist Therapeutics by 2.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 578,409 shares of the company’s stock worth $22,327,000 after purchasing an additional 12,906 shares in the last quarter. 98.63% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have commented on PTGX. Wedbush restated an “outperform” rating and set a $70.00 price target on shares of Protagonist Therapeutics in a research note on Friday, March 28th. JPMorgan Chase & Co. upped their price target on Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 4th. Truist Financial upped their price target on Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a “buy” rating in a research note on Tuesday, March 11th. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Protagonist Therapeutics in a research note on Thursday, April 10th. Finally, BMO Capital Markets upped their price target on Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 11th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Protagonist Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $65.44.

Insider Activity at Protagonist Therapeutics

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the firm’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total transaction of $204,606.62. Following the transaction, the chief executive officer now owns 540,260 shares of the company’s stock, valued at approximately $20,627,126.80. This trade represents a 0.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Asif Ali sold 24,903 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $58.73, for a total value of $1,462,553.19. Following the transaction, the chief financial officer now directly owns 62,821 shares in the company, valued at approximately $3,689,477.33. The trade was a 28.39% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 66,532 shares of company stock valued at $3,665,786 over the last quarter. 5.40% of the stock is owned by insiders.

Protagonist Therapeutics Trading Down 2.0%

Shares of NASDAQ PTGX opened at $43.04 on Monday. The stock has a market cap of $2.67 billion, a P/E ratio of 16.18 and a beta of 2.65. Protagonist Therapeutics, Inc. has a 12-month low of $27.00 and a 12-month high of $60.60. The business’s fifty day simple moving average is $46.95 and its 200-day simple moving average is $42.67.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Tuesday, May 6th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.31. The firm had revenue of $28.32 million for the quarter, compared to analyst estimates of $30.44 million. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. On average, equities analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.